一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）在接受新辅助化疗后手术的非小细胞肺癌患者中的预后价值
英文原题：The prognostic value of tumor-infiltrating lymphocytes in non-small cell lung cancer patients who received neoadjuvant chemotherapy followed by surgery.
查看英文原题
The prognostic value of tumor-infiltrating lymphocytes in non-small cell lung cancer patients who received neoadjuvant chemotherapy followed by surgery.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在接受新辅助化疗后手术的非小细胞肺癌患者中，中至高水平的 TILs 与良好预后相关。
中文摘要
背景
接受新辅助化疗后手术的非小细胞肺癌（NSCLC）患者，其TIL（肿瘤浸润淋巴细胞）水平与预后的关系仍需进一步研究。
目的
评估此类NSCLC患者TIL水平的预后价值。
材料与方法
回顾性纳入2014年12月至2020年12月在本院接受新辅助化疗后手术的NSCLC患者。对手术切除的肿瘤组织切片进行苏木精-伊红（H&E）染色，以评估TIL水平。按照推荐的TIL评估标准，将患者分为TIL低水平浸润组和TIL⁺（中至高水平浸润）组。采用单变量（Kaplan–Meier）和多变量（Cox）生存分析，研究临床病理特征及TIL水平对预后的影响。
结果
研究共纳入137例患者，其中45例为TIL低水平组，92例为TIL⁺组。TIL⁺组的总生存期（OS）和无病生存期（DFS）中位数均高于TIL低水平组。单变量分析显示，吸烟、临床和病理分期及TIL水平是影响OS和DFS的因素。多变量分析显示，吸烟（OS：风险比［HR］1.881，95%置信区间［CI］1.135–3.115，p=0.014；DFS：HR 1.820，95% CI 1.181–2.804，p=0.007）以及临床III期（DFS：HR 2.316，95% CI 1.350–3.972，p=0.002）是不良预后因素。同时，TIL⁺状态是OS（HR 0.547，95% CI 0.335–0.894，p=0.016）和DFS（HR 0.445，95% CI 0.284–0.698，p=0.001）的良好预后独立因素。
结论
中至高水平TIL与接受新辅助化疗后手术的NSCLC患者良好预后相关。TIL水平在该患者群体中具有预后价值。
展开英文摘要原文
BACKGROUND
The relationship between tumor-infiltrating lymphocyte (TIL) levels and the prognosis of patients with non-small cell lung cancer (NSCLC) who receive neoadjuvant chemotherapy followed by surgery is a problem that requires more research.
OBJECTIVES
To evaluate the prognostic value of TIL levels in patients with NSCLC who received neoadjuvant chemotherapy followed by surgery. MATERIAL AND METHODS: Patients with NSCLC who received neoadjuvant chemotherapy followed by surgery in our hospital from December 2014 to December 2020 were selected for a retrospective analysis. Sections were stained with hematoxylin and eosin (H&E) to evaluate TIL levels in surgically-resected tumor tissues. Patients were divided into TIL(low-level infiltration) and TIL+ (mediumto high-level infiltration) groups according to the recommended TIL evaluation criteria. Univariate (Kaplan-Meier) and multivariate (Cox) survival analyses were used to analyze the impact of clinicopathological features and TIL levels on prognosis.
RESULTS
The study involved 137 patients, including 45 who were TILand 92 who were TIL+. The median overall survival (OS) and disease-free survival (DFS) of the TIL+ group were higher than those of the TILgroup. The univariate analysis showed that smoking, clinical and pathological stages, and TIL levels, were the factors influencing OS and DFS. The multivariate analysis showed that smoking (OS, hazard ratio (HR): 1.881, 95% confidence interval (95% CI): 1.135-3.115, p = 0.014; DFS, HR: 1.820, 95% CI: 1.181-2.804, p = 0.007) and clinical stage III (DFS, HR: 2.316, 95% CI: 1.350-3.972, p = 0.002) were adverse factors affecting the prognosis of patients with NSCLC who received neoadjuvant chemotherapy followed by surgery. At the same time, TIL+ status was an independent factor for a good prognosis in OS (HR: 0.547, 95% CI: 0.335-0.894, p = 0.016) and DFS (HR: 0.445, 95% CI: 0.284-0.698, p = 0.001).
CONCLUSIONS
Medium to high levels of TILs were associated with a good prognosis in NSCLC patients who received neoadjuvant chemotherapy followed by surgery. The levels of TILs are of prognostic value in this population of patients.
论文信息
- 作者
- Hou Z、Zhao L、Zou L、Li B
- 第一作者单位
- Department of Oncology, The Second Affiliated Hospital, Guizhou Medical University, Kaili, China.China
- 通讯作者单位
- Department of Pathology, The Second Affiliated Hospital, Guizhou Medical University, Kaili, China.China
- 期刊
- Advances in clinical and experimental medicine : official organ Wroclaw Medical University2023 Aug
- 原文标识
- PubMed 36881364 · DOI 10.17219/acem/159242